![]() |
市場調査レポート
商品コード
1797676
コラーゲンおよびヒアルロン酸関節内注射の世界市場:製品タイプ・用途・流通経路・地域別 (~2035年)Global Collagen and Hyaluronic Acid Intra-Articular Injections Market by Product Type, by Application, by Distribution Channel, and by Region Forecast till 2035 |
||||||
|
コラーゲンおよびヒアルロン酸関節内注射の世界市場:製品タイプ・用途・流通経路・地域別 (~2035年) |
出版日: 2025年07月16日
発行: Market Research Future
ページ情報: 英文 184 Pages
納期: 即納可能
![]() |
世界のコラーゲンおよびヒアルロン酸関節内注射の市場規模は、予測期間中にCAGR 6.15%で推移し、2035年には63億2,480万米ドルに達すると予測されています。
ヒアルロン酸とコラーゲンは、関節疾患の治療のために関節に直接注射されます。ヒアルロン酸は理想的な潤滑剤および衝撃吸収材とされ、一方コラーゲンは軟骨の最も基本的な構成単位から形成され、軟骨の構造と再生を支えます。硬直や痛みを軽減することで、患者は失われた機能や可動性を取り戻し、最終的には手術回避へとつながる大きな一歩となります。
製造業者は、変形性関節症、関節リウマチ、スポーツ外傷などの高い発症率による需要に応えようとしており、コラーゲンとヒアルロン酸はその解決策としてますます人気を集めています。高齢化の進行や肥満、運動不足といったリスク因子の増加により、患者は非外科的治療を選択する傾向が強まっています。これらの注射は関節機能を高め、高額な手術を先延ばしにする大きな役割を果たしており、それが世界的に安定した市場成長の理由となっています。
北米は、患者教育の水準が高く、関節内薬剤の早期導入が行われたことから、世界市場の収益の大部分を占めています。米国は北米のコラーゲンおよびヒアルロン酸関節内注射市場を主導しており、その規模は12億1,126万米ドルに達し、カナダが1億7,035万米ドルで続いており、同地域における強い需要を示しています。充実した保険適用と安定した臨床的改善結果に支えられ、米国市場はこれらの治療に対するアクセス性が非常に高くなっています。
欧州では、人口の平均寿命の延伸と高度な治療に対する需要によって市場拡大が続いています。ドイツが1億3,061万米ドルで欧州市場を牽引し、英国 (9,489万米ドル) 、フランス (8,334万米ドル) がこれに続く主要な寄与国です。広範な研究が行われていることや確立された医療ネットワークにより、ドイツとフランスは市場の大部分を占めています。
アジア太平洋地域は潜在力に満ちており、人口の多い国々で需要が急増しています。中国が1億2,742万米ドルでアジア太平洋地域最大のシェアを握り、インドが8,396万米ドルで続き、ともに地域成長を形作っています。日本の高速な技術エコシステムは革新を強力に後押しし、中国の膨大な患者層が数量ベースでの成長を牽引しています。
当レポートでは、世界のコラーゲンおよびヒアルロン酸関節内注射の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。
Global Collagen and Hyaluronic Acid Intra-Articular Injections Market by Product Type [Hyaluronic Acid Injection (Single Injection, Multiple Injection), Collagen Injection, Combination of Hyaluronic Acid and Collagen], by Application (Knee Osteoarthritis, Joint Pains, Veterinary Applications, Post-Operative Recovery, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035
Industry Overview
The global collagen and hyaluronic acid intra-articular injections market is projected to expand at a 6.15% CAGR, reaching an estimated value of USD 6,324.80 million by 2035. Hyaluronic acid and collagen are injected directly into joints to treat joint disorders. While hyaluronic acid is expected to be the perfect lubricant and shock absorber, collagen, formed of the most basic unit of cartilage, supports the cartilage structure and regeneration. To reduce the stiffness and pain, the patients get back their lost functions and mobility, and this becomes a great step towards the final idea of surgery discontinuance.
Manufacturers are seeking to supply the demand that comes from the high rate of Osteoarthritis, Rheumatoid Arthritis, and sports injuries affecting the joint, and collagen and hyaluronic acid are becoming more and more popular as the solution. Due to the aging of the population and proliferating risk factors like obesity and inactivity, patients tend to decide in favor of non-surgical therapies. These injections have a major role in enhancing the function of the joints and in postponing expensive surgeries, which is the reason for their steady market growth all over the world.
Key Company Development
Ono Pharmaceutical and Seikagaku Corporation have succeeded in reaching a new summit in May 2021 by releasing in Japan JOYCLU 30mg Intra-articular Injection (generic: diclofenac etalhyaluronate sodium), which is a new product. By using their own technology for the binding of hyaluronic acid and diclofenol, Seikagaku has produced a unique drug that not only provides better lubrication but also fights inflammation. Consequently, JOYCLU improves the performance of the joint and resolves the problem of treatment of osteoarthritis, which is an advanced disease in Japan due to the country's aging society issue. In the wake of this event, Seikagaku has decided to introduce the new product line, starting with HyLink, in August 2021. It was conceived as the most recent single-injection viscosupplement for knee osteoarthritis with the aim of simplifying treatment by cutting down the number of injections while delivering sustained relief. In this way, the company affirms not only the needs of the patients but also its commitment to the effectiveness of clinical practice and innovation in musculoskeletal care.
Major players in the global collagen and hyaluronic acid intra-articular injection market are Seikagaku Corporation, Bioventus, Inc., Anika Therapeutics, Inc., Zimmer Biomet, Sanofi, Fidia Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Ferring B.V., Dr. Reddy's Laboratories Ltd., Semical Biosurgery, Avanos Medical, Inc., and Maxigen Biotech Inc. (MBI).
Report Attribute Details
Market Size 2024 USD 3,046.46 Million
Market Size 2035 USD 6,324.80 Million
CAGR (2025-2035) 6.15%
Base Year 2024
Market Forecast Period 2025-2035
Historical Data 2019-2024
By Product Type: Hyaluronic acid Injection - 6.34%, Collagen Injection - 5.45%.
By Application: Knee Osteoarthritis - 6.52%, Joint Pains - 5.74%.
By Distribution Channel: Hospital Pharmacies - 6.37%, Retail Pharmacies - 5.36%.
North America captures most of the global earnings mainly due to the high level of patient education and the early introduction of intra-articular drugs. The U.S. dominates North America's collagen and hyaluronic acid intra-articular injections market at USD 1,211.26 million, with Canada ranking second at USD 170.35 million, highlighting the region's strong demand. Supported by substantial insurance coverage and consistent clinical improvement results, the U.S. market has great accessibility to these treatments.
In Europe, the market expansion continues to be supported by the longer life expectancy of the population and their demand for sophisticated therapies. Germany leads Europe's market at USD 130.61 million, with the UK (USD 94.89 million) and France (USD 83.34 million) following as other key contributors. Germany and France are the two countries that account for the largest part of the market due to the extensive research that has been carried out and the well-established medical networks.
The Asia-Pacific region is full of potential, and thus, the demand is booming in the heavily populated countries. China holds the largest share in Asia-Pacific with USD 127.42 million, whereas India follows with USD 83.96 million, together shaping regional growth.Japan's high-speed technological ecosystem is very supportive of innovation, and China's vast patient pool drives volume growth.
Latin America's market outlook is positive but uneven, with Brazil spearheading adoption due to private healthcare investments. Market expansion is slower in smaller economies due to limited awareness and constrained spending capacity.
The Middle East & Africa market is gradually strengthening with rising demand for orthopedic care. Gulf countries, supported by government-funded health programs, are early adopters of advanced injections. African nations face structural barriers, with access concentrated in urban areas.